- call +1-201-465-4211
- email sales@mrinsights.biz
The cholesterol lowering biologic drugs offers a new, revolutionary alternative for people fighting with cholesterol with the same old treatments. The old method of treating cholesterol elevated levels includes a change in diet and consuming statin pills to prevent the body from making more bad cholesterol. The new class of PCSK-9 inhibitors is being approved by the FDA which works by helping the liver flush out the bad cholesterol instead of preventing the body from making low-density lipoproteins. The FDA has till now approved only two drugs Praluent and Repatha, both made from living things. The PCSK-9 is a protein which binds to the receptors, those which are responsible for getting the bad cholesterol out of the body.
Scope of the Report:
This report focuses on the Cholesterol Lowering Biologic Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The cholesterol lowering biologics drug market is expected to boom owing to the number of population with high cholesterol levels, sedentary lifestyle and increasing research developments. According to the Indian Council of Medical Research, at least three-fourth of the country’s population has dyslipidemia, a condition where the individual has abnormal levels of triglycerides or cholesterol. The risk factors are obesity, hypertension poor lifestyle habits and diabetes. Moreover, the demand for biologics is driven by the dramatic shift in production technology and an expansion of targeted diseases.
The worldwide market for Cholesterol Lowering Biologic Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Amgen
Regeneron Pharmaceuticals
Alnylam Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
For Oral Administration
Injectable Drugs
Market Segment by Applications, can be divided into
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
There are 15 Chapters to deeply display the global Cholesterol Lowering Biologic Drugs market.
Chapter 1, to describe Cholesterol Lowering Biologic Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Cholesterol Lowering Biologic Drugs, with sales, revenue, and price of Cholesterol Lowering Biologic Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Cholesterol Lowering Biologic Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Cholesterol Lowering Biologic Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Cholesterol Lowering Biologic Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Cholesterol Lowering Biologic Drugs Introduction
1.2 Market Analysis by Type
1.2.1 For Oral Administration
1.2.2 Injectable Drugs
1.3 Market Analysis by Applications
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 Drug Stores
1.3.4 Online Sales
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Business Overview
2.1.2 Cholesterol Lowering Biologic Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Amgen Cholesterol Lowering Biologic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Regeneron Pharmaceuticals
2.2.1 Business Overview
2.2.2 Cholesterol Lowering Biologic Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Regeneron Pharmaceuticals Cholesterol Lowering Biologic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Alnylam Pharmaceuticals
2.3.1 Business Overview
2.3.2 Cholesterol Lowering Biologic Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Alnylam Pharmaceuticals Cholesterol Lowering Biologic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Cholesterol Lowering Biologic Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Cholesterol Lowering Biologic Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Cholesterol Lowering Biologic Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Cholesterol Lowering Biologic Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Cholesterol Lowering Biologic Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Cholesterol Lowering Biologic Drugs Market Analysis by Regions
4.1 Global Cholesterol Lowering Biologic Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Cholesterol Lowering Biologic Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Cholesterol Lowering Biologic Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
4.5 South America Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
5 North America Cholesterol Lowering Biologic Drugs by Countries
5.1 North America Cholesterol Lowering Biologic Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Cholesterol Lowering Biologic Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Cholesterol Lowering Biologic Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
6 Europe Cholesterol Lowering Biologic Drugs by Countries
6.1 Europe Cholesterol Lowering Biologic Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Cholesterol Lowering Biologic Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Cholesterol Lowering Biologic Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
6.3 UK Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
6.4 France Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Cholesterol Lowering Biologic Drugs by Countries
7.1 Asia-Pacific Cholesterol Lowering Biologic Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Cholesterol Lowering Biologic Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Cholesterol Lowering Biologic Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
7.5 India Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
8 South America Cholesterol Lowering Biologic Drugs by Countries
8.1 South America Cholesterol Lowering Biologic Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Cholesterol Lowering Biologic Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Cholesterol Lowering Biologic Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Cholesterol Lowering Biologic Drugs by Countries
9.1 Middle East and Africa Cholesterol Lowering Biologic Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Cholesterol Lowering Biologic Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Cholesterol Lowering Biologic Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Cholesterol Lowering Biologic Drugs Sales and Growth Rate (2013-2018)
10 Global Cholesterol Lowering Biologic Drugs Market Segment by Type
10.1 Global Cholesterol Lowering Biologic Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Cholesterol Lowering Biologic Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Cholesterol Lowering Biologic Drugs Revenue and Market Share by Type (2013-2018)
10.2 For Oral Administration Sales Growth and Price
10.2.1 Global For Oral Administration Sales Growth (2013-2018)
10.2.2 Global For Oral Administration Price (2013-2018)
10.3 Injectable Drugs Sales Growth and Price
10.3.1 Global Injectable Drugs Sales Growth (2013-2018)
10.3.2 Global Injectable Drugs Price (2013-2018)
11 Global Cholesterol Lowering Biologic Drugs Market Segment by Application
11.1 Global Cholesterol Lowering Biologic Drugs Sales Market Share by Application (2013-2018)
11.2 Hospital Pharmacies Sales Growth (2013-2018)
11.3 Retail Pharmacies Sales Growth (2013-2018)
11.4 Drug Stores Sales Growth (2013-2018)
11.5 Online Sales Sales Growth (2013-2018)
12 Cholesterol Lowering Biologic Drugs Market Forecast (2018-2023)
12.1 Global Cholesterol Lowering Biologic Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Cholesterol Lowering Biologic Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Cholesterol Lowering Biologic Drugs Market Forecast (2018-2023)
12.2.2 Europe Cholesterol Lowering Biologic Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Cholesterol Lowering Biologic Drugs Market Forecast (2018-2023)
12.2.4 South America Cholesterol Lowering Biologic Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Cholesterol Lowering Biologic Drugs Market Forecast (2018-2023)
12.3 Cholesterol Lowering Biologic Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Cholesterol Lowering Biologic Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Cholesterol Lowering Biologic Drugs Market Share Forecast by Type (2018-2023)
12.4 Cholesterol Lowering Biologic Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Cholesterol Lowering Biologic Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Cholesterol Lowering Biologic Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Cholesterol Lowering Biologic Drugs Picture
Table Product Specifications of Cholesterol Lowering Biologic Drugs
Figure Global Sales Market Share of Cholesterol Lower
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
